Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today announces that the Chinese National...

Telix jumps on maiden Chinese application for prostate imaging agent, but short selling increasing

Telix Pharma’s (ASX:TLX) got the Chinese market locked in its sights with a maiden application for Illuccix, a prostate cancer imaging agent, now lodged with (and accepted by) the National Medical Products Application (NMPA). Worth noting is this is just an acceptance of the application and not an approval of the drug for use; shares jumped around +4% in morning Tuesday trades. Listen to the HotCopper podcast for in-depth discussions and insight…

Telix Pharmaceuticals receives China’s nod for Illuccix prostate cancer imaging NDA

Telix Pharmaceuticals share price in focus as China’s NMPA accepts Illuccix NDA for prostate cancer imaging, marking a milestone for the company.